[Methylglucamine antimoniate and sodium stibogluconate in the treatment of leishmaniasis. Study of 16 cases].
Treatment of visceral and cutaneous leishmaniasis rests on pentavalent antimonial drugs. However, side effects are often a problem and resistance may emerge. N-methyl-glucamine given for kala-azar induced hematologic or hepatic toxicity in three patients and failed in two. Four patients with cutaneous leishmaniasis recovered but two exhibited adverse side effects. Sodium stibo-gluconate failed in one of three kala-azar patients and in one of two patients with cutaneous leishmaniasis. The effects of these two drugs are discussed, as well as indications of pentamidine and splenectomy.
D000293:Adolescent; D000328:Adult; D000965:Antimony / Q000009:adverse effects / Q000627:therapeutic use*; D000967:Antimony Sodium Gluconate / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005942:Gluconates / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007896:Leishmaniasis / Q000188:drug therapy* / Q000628:therapy; D007898:Leishmaniasis, Visceral / Q000188:drug therapy / Q000628:therapy; D008297:Male; D008536:Meglumine; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds; D010419:Pentamidine / Q000627:therapeutic use; D013156:Splenectomy
D005942:Gluconates; D009942:Organometallic Compounds; D010419:Pentamidine; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000965:Antimony; D000967:Antimony Sodium Gluconate
Antimoniate de méthyl-glucamine et stibo-gluconate de sodium dans le traitement des leishmanioses. Etude de seize cas.